Search Results - "Fogarty, Kate V."

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study by Brennan, Brian P., Fogarty, Kate V., Roberts, Jacqueline L., Reynolds, Karina A., Pope Jr, Harrison G., Hudson, James I.

“…Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily…”
Get full text

Memantine in the treatment of binge eating disorder: An open-label, prospective trial by Brennan, Brian P, Roberts, Jacqueline L, Fogarty, Kate V, Reynolds, Karina A, Jonas, Jeffrey M, Hudson, James I

“…OBJECTIVE:: To assess preliminarily the efficacy of memantine in binge eating disorder. METHOD:: This was an open-label, 12-week, flexible-dose (5-20 mg/day)…”
Get full text

Hospital use of antipsychotic drugs: polytherapy by Centorrino, Franca, Cincotta, Stephanie L, Talamo, Alessandra, Fogarty, Kate V, Guzzetta, Francesca, Saadeh, Mark G, Salvatore, Paola, Baldessarini, Ross J

“…Abstract Objective Growing acceptance of new psychotropic drugs encouraged a survey of current use of antipsychotic drugs alone and in combinations, with…”
Get full text

Antipsychotic drug use: McLean Hospital, 2002 by Centorrino, Franca, Fogarty, Kate V., Sani, Gabriele, Salvatore, Paola, Cimbolli, Paola, Baldessarini, Ross J.

“…Objective Major changes in antipsychotic treatment in recent years encouraged a survey of inpatient practice in 2002, compared with earlier samples. Methods…”
Get full text

Use of combinations of antipsychotics: McLean Hospital inpatients, 2002 by Centorrino, Franca, Fogarty, Kate V., Sani, Gabriele, Salvatore, Paola, Cincotta, Stephanie L., Hennen, John, Guzzetta, Francesca, Talamo, Alessandra, Saadeh, Mark G., Baldessarini, Ross J.

“…Background The empirical use of combinations of antipsychotic agents appears to be increasing with little research support for the relative efficacy, safety or…”
Get full text

Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients by Centorrino, Franca, Fogarty, Kate V, Cimbolli, Paola, Salvatore, Paola, Thompson, Terri-Ann, Sani, Gabriele, Cincotta, Stephanie L, Baldessarini, Ross J

“…Aripiprazole is the first dopamine D2 receptor partial-agonist approved for treatment of schizophrenia. Its apparently benign adverse-effect profile encourages…”
Get full text

Pilot Comparison of Extended-Release and Standard Preparations of Divalproex Sodium in Patients With Bipolar and Schizoaffective Disorders by Centorrino, Franca, Kelleher, James P., Berry, Judith M., Salvatore, Paola, Eakin, Marion, Fogarty, Kate V., Fellman, Veronica, Baldessarini, Ross J.

“…OBJECTIVE: The authors compared the new extended-release and standard preparations of divalproex sodium. METHOD: Twelve patients with DSM-IV bipolar disorder…”
Get full text

Oxcarbazepine: clinical experience with hospitalized psychiatric patients by Centorrino, Franca, Albert, Matthew J, Berry, Judith M, Kelleher, James P, Fellman, Veronica, Line, Gyorgy, Koukopoulos, Alexia E, Kidwell, Jennifer E, Fogarty, Kate V, Baldessarini, Ross J

“…Background: Oxcarbazepine (10‐keto‐carbamazepine) appears to be better tolerated and simpler to use than carbamazepine. It has antimanic effects but, as its…”
Get full text

Ziprasidone: first year experience in a hospital setting by Centorrino, Franca, MacLean, Elizabeth, Salvatore, Paola, Kidwell, Jennifer E, Fogarty, Kate V, Berry, Judith M, Baldessarini, Ross J

“…The antipsychotic drug ziprasidone, FDA-approved and introduced in the United States in February 2001 for the treatment of schizophrenia, appears to have…”
Get full text